Abstract: Disclosed herein is a liquid pharmaceutical formulation substantially free of water, comprising: (i) amlodipine or a pharmaceutically acceptable salt thereof, (ii) at least one pharmaceutically acceptable excipient, and (iii) a sufficient amount of a vehicle comprising glycerin. Also disclosed herein is a liquid pharmaceutical formulation substantially free of water and ethanol, comprising: (i) amlodipine or a pharmaceutically acceptable salt thereof, (ii) at least one pharmaceutically acceptable excipient, and (iii) a sufficient amount of a vehicle comprising glycerin.

Abstract: Disclosed herein is a liquid pharmaceutical formulation substantially free of water, comprising: (i) amlodipine or a pharmaceutically acceptable salt thereof, (ii) at least one pharmaceutically acceptable excipient, and (iii) a sufficient amount of a vehicle comprising glycerin. Also disclosed herein is a liquid pharmaceutical formulation substantially free of water and ethanol, comprising: (i) amlodipine or a pharmaceutically acceptable salt thereof, (ii) at least one pharmaceutically acceptable excipient, and (iii) a sufficient amount of a vehicle comprising glycerin.

Abstract: Disclosed herein is a liquid pharmaceutical formulation substantially free of water, comprising: (i) amlodipine or a pharmaceutically acceptable salt thereof, (ii) at least one pharmaceutically acceptable excipient, and (iii) a sufficient amount of a vehicle comprising glycerin. Also disclosed herein is a liquid pharmaceutical formulation substantially free of water and ethanol, comprising: (i) amlodipine or a pharmaceutically acceptable salt thereof, (ii) at least one pharmaceutically acceptable excipient, and (iii) a sufficient amount of a vehicle comprising glycerin.

Abstract: The present invention discloses liquid dosage forms of apixaban in the form of aqueous & non-aqueous solutions for oral administration. The formulations of the present invention can include higher amount of apixaban with lower amount of solvent and/or vehicles.

Abstract: Disclosed herein is a liquid pharmaceutical formulation substantially free of water, comprising: (i) amlodipine or a pharmaceutically acceptable salt thereof, (ii) at least one pharmaceutically acceptable excipient, and (iii) a sufficient amount of a vehicle comprising glycerin. Also disclosed herein is a liquid pharmaceutical formulation substantially free of water and ethanol, comprising: (i) amlodipine or a pharmaceutically acceptable salt thereof, (ii) at least one pharmaceutically acceptable excipient, and (iii) a sufficient amount of a vehicle comprising glycerin.

Abstract: Disclosed herein is a liquid pharmaceutical formulation substantially free of water, comprising: (i) amlodipine or a pharmaceutically acceptable salt thereof, (ii) at least one pharmaceutically acceptable excipient, and (iii) a sufficient amount of a vehicle comprising glycerin. Also disclosed herein is a liquid pharmaceutical formulation substantially free of water and ethanol, comprising: (i) amlodipine or a pharmaceutically acceptable salt thereof, (ii) at least one pharmaceutically acceptable excipient, and (iii) a sufficient amount of a vehicle comprising glycerin.

Abstract: Disclosed herein is a liquid pharmaceutical formulation substantially free of water, comprising: (i) amlodipine or a pharmaceutically acceptable salt thereof, (ii) at least one pharmaceutically acceptable excipient, and (iii) a sufficient amount of a vehicle comprising glycerin. Also disclosed herein is a liquid pharmaceutical formulation substantially free of water and ethanol, comprising: (i) amlodipine or a pharmaceutically acceptable salt thereof, (ii) at least one pharmaceutically acceptable excipient, and (iii) a sufficient amount of a vehicle comprising glycerin.

Abstract: The present disclosure provides a device including a cylindrical member having a distal end and a proximal end. The cylindrical member includes a plurality of longitudinal slits positioned between the distal end and the proximal end to thereby create a plurality of strips positioned between the plurality of longitudinal slits. The device also includes an elongated hollow tube having a distal end and a proximal end. The elongated hollow tube is coupled to the proximal end of the cylindrical member. The device also includes a rod having a distal end and a proximal end.

Abstract: Disclosed herein is a liquid pharmaceutical formulation substantially free of water, comprising: (i) amlodipine or a pharmaceutically acceptable salt thereof, (ii) at least one pharmaceutically acceptable excipient, and (iii) a sufficient amount of a vehicle comprising glycerin. Also disclosed herein is a liquid pharmaceutical formulation substantially free of water and ethanol, comprising: (i) amlodipine or a pharmaceutically acceptable salt thereof, (ii) at least one pharmaceutically acceptable excipient, and (iii) a sufficient amount of a vehicle comprising glycerin.

Abstract: Disclosed herein is a liquid pharmaceutical formulation substantially free of water, comprising: (i) amlodipine or a pharmaceutically acceptable salt thereof, (ii) at least one pharmaceutically acceptable excipient, and (iii) a sufficient amount of a vehicle comprising glycerin. Also disclosed herein is a liquid pharmaceutical formulation substantially free of water and ethanol, comprising: (i) amlodipine or a pharmaceutically acceptable salt thereof, (ii) at least one pharmaceutically acceptable excipient, and (iii) a sufficient amount of a vehicle comprising glycerin.

Abstract: Disclosed herein is an oral pharmaceutical solution, comprising: about 0.5 mg/mL to about 120 mg/mL of clopidogrel or a pharmaceutically acceptable salt thereof; about 35 mg/mL to about 200 mg/mL propylene glycol; one or more pharmaceutically acceptable excipients; and a vehicle comprising glycerin; wherein the oral pharmaceutical solution has an amount of water of less than or equal to 5% w/w and an amount of ethanol less than or equal to 6% w/w. Oral pharmaceutical solution disclosed herein have a clopidogrel content of 100±10% when stored for about 24 months at 25° C.±2° C. and 60±5% relative humidity.

Abstract: Systems and methods including one or more processors and one or more non-transitory storage devices storing computing instructions configured to run on the one or more processors and perform receiving a sequence of actions entered into a GUI before an account action for a user account of a user during a user session initiated via a first user portal; dividing the sequence of actions into actions for real-time features and actions for periodic features; simultaneously (1) storing the actions for the periodic features in a distributed cloud storage system and (2) processing the actions for the real-time features into the real-time features; and simultaneously storing the periodic features and the real-time features in a database managed by real-time stream processing software.

Abstract: Disclosed herein is a liquid pharmaceutical formulation substantially free of water, comprising: (i) amlodipine or a pharmaceutically acceptable salt thereof, (ii) at least one pharmaceutically acceptable excipient, and (iii) a sufficient amount of a vehicle comprising glycerin. Also disclosed herein is a liquid pharmaceutical formulation substantially free of water and ethanol, comprising: (i) amlodipine or a pharmaceutically acceptable salt thereof, (ii) at least one pharmaceutically acceptable excipient, and (iii) a sufficient amount of a vehicle comprising glycerin.

Abstract: Disclosed herein is a liquid pharmaceutical formulation substantially free of water, comprising: (i) amlodipine or a pharmaceutically acceptable salt thereof, (ii) at least one pharmaceutically acceptable excipient, and (iii) a sufficient amount of a vehicle comprising glycerin. Also disclosed herein is a liquid pharmaceutical formulation substantially free of water and ethanol, comprising: (i) amlodipine or a pharmaceutically acceptable salt thereof, (ii) at least one pharmaceutically acceptable excipient, and (iii) a sufficient amount of a vehicle comprising glycerin.

Abstract: Conventional injectable formulations of Diclofenac are known to have excipients which cause irritation at the site of injection and are painful. Further, such conventional formulations also cause thrombophlebitis. Other injectable formulations of Diclofenac known in the prior art also contain excipients which are tissue irritants and may cause toxicity when administered through intravenous route. The cyclodextrin compounds used in Dyloject® may cause problems while elimination in the renal compromised patients. The present invention therefore provides injectable Diclofenac formulations which do not cause irritation and pain at the site of injection. Further, the formulations of the present invention do not include cyclodextrins, therefore can also be administered to the renal compromised patients.

Abstract: Disclosed herein is a liquid pharmaceutical formulation substantially free of water, comprising: (i) amlodipine or a pharmaceutically acceptable salt thereof, (ii) at least one pharmaceutically acceptable excipient, and (iii) a sufficient amount of a vehicle comprising glycerin. Also disclosed herein is a liquid pharmaceutical formulation substantially free of water and ethanol, comprising: (i) amlodipine or a pharmaceutically acceptable salt thereof, (ii) at least one pharmaceutically acceptable excipient, and (iii) a sufficient amount of a vehicle comprising glycerin.

Abstract: Systems and methods including one or more processors and one or more non-transitory storage devices storing computing instructions configured to run on the one or more processors and perform receiving a sequence of actions entered into a GUI before an account action for a user account of a user during a user session initiated via a first user portal; dividing the sequence of actions into actions for real-time features and actions for periodic features; simultaneously (1) storing the actions for the periodic features in a distributed cloud storage system and (2) processing the actions for the real-time features into the real-time features; and simultaneously storing the periodic features and the real-time features in a database managed by real-time stream processing software.

Abstract: Edaravone, in the United States, is approved in the form of ready-to-use intravenous solution for infusion, RADICAVA. RADICAVA injection is supplied in a polypropylene bag overwrapped with polyvinyl alcohol (PVA) secondary packaging. Edaravone is susceptible to oxidation and the overwrapped package also contains an oxygen absorber and oxygen indicator to minimize oxidation. Various efforts have been put in the art for packaging edaravone drug solution in different types of packaging materials, for example, plastic containers and glass bottles to prevent edaravone from oxidation and other degradation. The present invention involves use of simple and economic container-closure system for packaging edaravone drug solution while maintaining its stability during storage, transportation and use which includes glass bottles or vials and closures made of elastic polymer or rubber (for example elastomer, isoprene rubber or butyl rubber and the like).

Abstract: Disclosed herein is a liquid pharmaceutical formulation substantially free of water, comprising: (i) amlodipine or a pharmaceutically acceptable salt thereof, (ii) at least one pharmaceutically acceptable excipient, and (iii) a sufficient amount of a vehicle comprising glycerin. Also disclosed herein is a liquid pharmaceutical formulation substantially free of water and ethanol, comprising: (i) amlodipine or a pharmaceutically acceptable salt thereof, (ii) at least one pharmaceutically acceptable excipient, and (iii) a sufficient amount of a vehicle comprising glycerin.

Abstract: Levothyroxine sodium for injection is particularly useful when thyroid replacement is needed on an urgent basis, for short term thyroid replacement, and/or when oral administration is not possible, such as for a patient in a state of myxedema coma. The present invention is therefore related to the liquid parenteral compositions comprising Levothyroxine or its pharmaceutically acceptable salt. In particular, the present invention describes ready to dilute liquid compositions which may be diluted using suitable diluent before administering to the patient in need thereof.